Atossa Therapeutics
ATOS
66 hedge funds and large institutions have $16.8M invested in Atossa Therapeutics in 2025 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 11 increasing their positions, 25 reducing their positions, and 27 closing their positions.
92% more call options, than puts
Call options by funds: $221K | Put options by funds: $115K
0.1% less ownership
Funds ownership: 1.1% → 1% (-0.1%)
5% less capital invested
Capital invested by funds: $17.7M → $16.8M (-$918K)
21% less funds holding
Funds holding: 84 → 66 (-18)
56% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 25
67% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$214K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$202K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$145K |
| 4 |
GCM
Graham Capital Management
Rowayton,
Connecticut
|
+$136K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$80.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
YIH
Y-Intercept (HK)
Hong Kong
|
-$321K |
| 2 |
Millennium Management
New York
|
-$312K |
| 3 |
Goldman Sachs
New York
|
-$278K |
| 4 |
Jane Street
New York
|
-$244K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$229K |
ATOS Hedge Fund Activity: Q3 2025 in Review
66 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q3 2025, worth a combined $16.8M — down 5.2% from $17.7M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of ATOS and 9 opened new positions — a net loss of 18 holders — while 25 trimmed existing stakes and 11 added.
The largest buyer was GSA Capital Partners, adding an estimated $214K. The largest seller was Y-Intercept (HK), exiting entirely with an estimated $321K sold.
- 66 institutional investors held Atossa Therapeutics (ATOS) as of Q3 2025, down from 84 in Q2 2025.
- Funds reported $16.8M of Atossa Therapeutics stock for Q3 2025, down 5.2% quarter-over-quarter.
- 9 funds opened new Atossa Therapeutics positions in Q3 2025 and 27 closed out, a net change of -18 holders.
- The largest Atossa Therapeutics buyer in Q3 2025 was GSA Capital Partners, an estimated $214K added.
- The largest Atossa Therapeutics seller in Q3 2025 was Y-Intercept (HK), an estimated $321K sold.
Based on aggregated 13F filings for Q3 2025.